Genmap-Pro™
AI-powered preclinical derisking for biotech, pharma and investors
Genmap-Pro helps biotech companies, pharma R&D teams and investors assess the biological, chemical and translational risk of drug discovery programs before committing significant experimental or financial resources.
A decision-support platform for early R&D and investment decisions
Genmap-Pro is designed to help answer critical questions:
- Is the biological rationale strong enough?
- Is the target aligned with the disease mechanism?
- Are the proposed molecules likely to be active and selective?
- Are there early ADME/Tox or safety liabilities?
- What should be tested next experimentally?
- Is the program ready for further investment, partnership or due diligence?
Designed for decision-makers
Biotech CEOs & CSOs
Prioritize programs, challenge scientific assumptions and prepare investor-ready narratives.
Pharma R&D teams
Support target assessment, asset evaluation and early preclinical strategy.
Investors & due diligence teams
Obtain an independent, structured and scientifically grounded view of asset risk.
Academic translational teams
Evaluate therapeutic hypotheses and identify the most relevant next experiments.
What we offer
- Flash Due Diligence
A rapid 1–2 week assessment to identify early red flags, opportunities and Go / No-Go signals. - Asset Deep Dive
A comprehensive scientific evaluation of a drug discovery asset, integrating biology, activity, selectivity, ADME/Tox, safety and strategic recommendations. - Rare Disease Explorer
A dedicated workflow for rare diseases and poorly documented mechanisms, from biological rationale to candidate prioritization. - Candidate Sprint
An AI-guided generation and evaluation workflow to explore, rank and prioritize new molecular options. - Strategic Partnership
A long-term collaboration model for recurring analyses, dashboards, scientific reviews and strategic decision support.
